What is GeNO?
GeNO LLC is a biopharmaceutical company dedicated to advancing inhaled nitric oxide (NO) therapies for critical unmet medical needs in pulmonary and cardiac conditions. Its proprietary GeNOsyl® drug delivery technology features a unique drug cassette system paired with portable or wearable controllers, facilitating safe and effective NO administration in both acute hospital settings and for long-term outpatient use. The company's lead product, GeNOsyl Acute DS, is designed for precise NO delivery to ventilated patients, with an emphasis on ease of use. GeNO's core innovation lies in its chemistry-first approach, which addresses the issue of nitrogen dioxide (NO2) co-delivery inherent in traditional NO systems. By generating nitric oxide rapidly and quantitatively through a chemical process, GeNO aims to enhance safety and efficacy compared to existing treatments. The company is actively pursuing clinical studies for NO as both a diagnostic agent and a therapeutic in areas like pulmonary arterial hypertension.
How much funding has GeNO raised?
GeNO has raised a total of $54.8M across 4 funding rounds:
Private Equity
$2.1M
Private Equity
$8M
Private Equity
$14.7M
Private Equity
$29.9M
Private Equity (2009): $2.1M, investors not publicly disclosed
Private Equity (2011): $8M, investors not publicly disclosed
Private Equity (2013): $14.7M, investors not publicly disclosed
Private Equity (2017): $29.9M, investors not publicly disclosed
What's next for GeNO?
With a significant enterprise-level funding base and a recent strategic investment, GeNO is well-positioned to accelerate its development pipeline and commercialization efforts. The company's focus on its proprietary GeNOsyl® technology and its differentiated chemistry platform suggests a strategic push towards clinical validation and market entry for its inhaled NO products. Future endeavors will likely involve advancing its active Investigational New Drug Applications (INDs) through further clinical trials, potentially expanding its therapeutic indications, and scaling its manufacturing capabilities to meet anticipated market demand. The sustained capital infusion signals a commitment to overcoming regulatory hurdles and establishing GeNO as a key player in the respiratory and cardiovascular therapeutic landscape.
See full GeNO company page
